"Hapoalim Securities expects that areas such as oncology and neurology -- \"specialty indications containing several significant unmet needs -- are likely to represent the preferred targets for acquisitions and licensing arrangements by Japanese companies, given the more favorable reimbursement environment in these areas, he said." . . . . .